Signaling Pathways - Vascular Disrupting Agents (VDA) - Sphingosine kinases (SphKs) - calcium uptake - Insulin and Insulin-like Receptors
清除全部
- B1298 K145Target: Sphingosine kinases (SphKs)Summary: SphK2抑制剂
- B2298 Plinabulin (NPI-2358)中文名: 普那布林Target: Vascular Disrupting Agents (VDA)Summary: 血管破坏剂
- B2226 SKI IITarget: Sphingosine kinases (SphKs)Summary: 鞘氨醇激酶(SK)抑制剂
- A8510 Ranolazine1 Citation中文名: 雷诺嗪Target: calcium uptakeSummary: 抗缺血
- A8440 GSK1838705ATarget: Insulin and Insulin-like Receptors|ALKSummary: ATP竞争性IGF-IR/IR/ALK抑制剂
- A1302 GSK1904529ATarget: Insulin and Insulin-like ReceptorsSummary: IGF-1R/IR 选择性抑制剂
- A1185 BMS-754807Target: Insulin and Insulin-like ReceptorsSummary: 有效的、选择性的IGF-1R和InsR抑制剂
- A3717 PF-5431 CitationTarget: Sphingosine kinases (SphKs)Summary: SphK1选择性抑制剂
- A3608 MK 0893Target: Insulin and Insulin-like Receptors|Glucagon ReceptorsSummary: 胰高血糖素受体/ IGF-1R拮抗剂
- A4302 Rosiglitazone maleate中文名: 马来酸罗格列酮Target: Insulin and Insulin-like ReceptorsSummary: PPARγ激动剂,有效的胰岛素敏化剂